SORD
-
Pharmaceutical giants set to lose dominance in urological disorders market
Major pharmaceutical companies are predicted to lose their footing in the urological disorders market by 2017, a report by GBI Research has found.
SORD | 17 May 2012
-
Collaborating in the field of epigenetic disorders
Nuevolution has entered into a lead discovery collaboration focused on epigenetic disorders. A consortium between Nuevolution, EpiTherapeutics, ExpreS2ion Biotechnologies and the research group of Professor Kristian Helin (Biotech Research & Innovat…
SORD | 29 October 2010
-
Treating hearing loss and balance disorders
GenVec announces a new agreement for the supply of services relating to development materials with Novartis, related to the companies' collaboration in hearing loss and balance disorders. Under this new agreement, GenVec could receive approximately …
SORD | 30 August 2010
-
“Lost Chemistry†Database to Aid Pharma Research
Selected Organic Reactions Database (SORD) and Advanced Chemistry Development (ACD/Labs) are offering the first version of a compound and reaction library as a commercial database that is available for use with ACD/ChemFolder or ACD/Web Librarian. …
SORD | 10 March 2010
-
S*Bio: Jak2 Inhibitor Demonstrates Safety in Studies for Myeloproliferative Disorder
S*BIO has announced data presentations on its oral JAK2 inhibitor, SB1518. Data will be presented on the clinical results from the Phase 1 dose-escalation trial of SB1518 detailing its safety, tolerability and pharmacokinetic/pharmacodynamic (PK/PD) …
SORD | 09 December 2009
-
Imaging Technology: Aiding in Disease Detection
Elemental Bio-Imaging (EBI) offers a means of accurately identifying trace metals that are responsible for neurological disorders.
SORD | 01 September 2009
-
AstraZeneca to Initiate Phase IIb Studies for ADHD
AstraZeneca plans to conduct further development of AZD3480 by initiating Phase IIb studies in attention deficit/hyperactivity disorder (ADHD). It has agreed to make a US$10 million milestone payment to Targacept. The company also plans to continue t…
SORD | 27 July 2009
-
FDA approves Banzel for adjunctive treatment for severe epilepsy disorder
Eisai Corp of North America says the US Food and Drug Administration (FDA) has approved Banzel (rufinamide) for the adjunctive treatment of seizures associated with Lennox-Gastaut syndrome (LGS) in children four years and older and adults. LGS is…
SORD | 20 November 2008
-
AstraZeneca announces European Seroquel XR submission for the treatment of GAD
AstraZeneca has its submission of Seroquel XR (quetiapine fumarate extended release tablets) to European regulatory authorities seeking approval for both short-term and maintenance treatment of Generalised Anxiety Disorder (GAD). This is the firs…
SORD | 21 October 2008
-
Cymbalta receives European approval to treat GAD
Eli Lilly and Co and Boehringer Ingelheim say the European Commission has approved the use of Cymbalta (duloxetine) for the treatment of generalised anxiety disorder (GAD). This approval – the fourth for duloxetine in Europe - was issued on 28 …
SORD | 25 August 2008
